A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies (CaDAnCe-101)
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies
Sponsor: BeOne Medicines
A observational or N/A phase clinical study on B-cell Malignancy and Chronic Lymphocytic Leukemia, this trial is actively recruiting participants. The trial is conducted by BeOne Medicines and has accumulated 41 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Study Description(click to expand)Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.
Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.
Status Flow
Change History
41 versions recorded-
Apr 23, 2026 — Present [daily]
Recruiting
-
Apr 16, 2026 — Apr 23, 2026 [daily]
Recruiting
Phase: PHASE1/PHASE2 → None
-
Mar 2026 — Apr 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Feb 2026 — Mar 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Dec 2025 — Feb 2026 [monthly]
Recruiting PHASE1/PHASE2
▶ Show 36 earlier versions
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2025 — Aug 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE1/PHASE2
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Mar 2025 — Apr 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Feb 2025 — Mar 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jan 2025 — Feb 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Nov 2024 — Jan 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2024 — May 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2023 — Feb 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE1_PHASE2
Phase: PHASE1 → PHASE1_PHASE2
-
Sep 2023 — Nov 2023 [monthly]
Recruiting PHASE1
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE1
-
Apr 2023 — Aug 2023 [monthly]
Recruiting PHASE1
-
Feb 2023 — Apr 2023 [monthly]
Recruiting PHASE1
-
Nov 2022 — Feb 2023 [monthly]
Recruiting PHASE1
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE1
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE1
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE1
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE1
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE1
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE1
-
Nov 2021 — Mar 2022 [monthly]
Recruiting PHASE1
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
Contact Information
- BeOne Medicines
For direct contact, visit the study record on ClinicalTrials.gov .